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INTRODUCTION
The use of methotrexate (MTX) for medical treatment of
women with tubal ectopic pregnancy was first introduced
in 1982, and has now come to be widely accepted. Addition-
ally, the role of MTX has become more important as a con-
sequence of the current widespread availability of the early
diagnosis of ectopic pregnancy. 
Initially, MTX has been used in a multi-dose regimen with
citrovorum rescue factor (1, 2). It was then documented that
ectopic pregnancy was successfully treated with a single intra-
muscular injection of MTX (3, 4). Success rates of the single-
dose regimen in the treatment of ectopic pregnancy have
been reported to range from approximately 75% to greater
than 90% (4-6) with lower toxic side effects, fewer compli-
cations, and better acceptance by patients when compared
to multi-dose regimens (7). 
Although predictors of success of the single-dose regimen
are widely known from various studies, the success predic-
tors of repeated injections of MTX, due to the decline of  -
hCG level less than 15% between days 4 and 7, have not
yet been acknowledged. For this reason, when repeated injec-
tions are used, doctors and patients tend to fear failure, espe-
cially when  -hCG level increases markedly between days 4
and 7. This often leads to the decision of elective operation,
rather than attempting the additional injections of MTX.
The purpose of this study is to evaluate predictors of suc-
cess of repeated injections in the single-dose regimen for the
treatment of tubal ectopic pregnancy.
MATERIALS AND METHODS
Between January 2001 and December 2003, all patients
who had tubal ectopic pregnancy and were treated with a
single-dose regimen were retrospectively identified from hos-
pital records of the Department of Obstetrics and Gynecol-
ogy in the Korea University Medical Center. The diagnosis
of tubal pregnancy was made using both transvaginal ultra-
sonography (TVU) and measurement of  -hCG level. Uter-
ine curretage was performed only when clinically indicated.
Ectopic pregnancy was diagnosed when adnexal mass or ex-
trauterine tubal gestational sac without intrauterine gesta-
tion was observed with TVU and when patients had inap-
propriately rising  -hCG levels (slower doubling time after
one to two consecutive  -hCG level determinations). 
An operation was performed on hemodynamically unsta-
ble patients with signs and symptoms of rupture, as well as
for patients who refused medical treatment with MTX and
close follow-up. Patients were not excluded from MTX ther-
apy by a selected initial  -hCG level or by the presence of
fetal cardiac activity observed by TVU.
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Predictors of Success of Repeated Injections of Single-dose
Methotrexate Regimen for Tubal Ectopic Pregnancy 
The purpose of this study is to evaluate predictors of success of repeated injections
of methotrexate in the single-dose regimen for the treatment of tubal ectopic preg-
nancy. All patients who had ectopic tubal pregnancy and were treated with a single
dose regimen were retrospectively identified. 126 patients were treated with metho-
trexate. Among them, 39 patients were adequate for this study. 33 were treated
with the 2nd dose and 27 were successfully cured. Additionally, 6 who were inject-
ed with the 3rd dose were all cured as well. Therefore, in our study, the success
rate for the repeated injections of methotrexate was found to be 84.6% (33/39). The
mean initial  -hCG level was significantly lower in patients who were successfully
treated than in patients who failed (3915.3±3281.3 vs. 8379.7±2604.4 IU/mL, p<
0.05). The success rate is 96% when the  -hCG level is less than 6,000 IU/mL and
is 58% when  -hCG is greater than 6,000 IU/mL (OR=18.57, 95% CI 1.86-185.89).
The initial  -hCG level is the only factor that has significant meaning as predictor
of success of repeated injections of methotrexate in the single-dose regimen. Repeat-
ed injections of methotrexate may be particularly effective when the initial  -hCG
level is below 6,000 IU/mL.
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All patients were treated with a single IM dose (50 mg/m2)
of MTX. Before MTX therapy, each patient was informed
about the possible side effects of MTX or tubal rupture and
intraabdominal hemorrhage, which would necessitate surgery.
-hCG levels were measured on days 4 and 7 after the injec-
tion. Patients received an injection of MTX if their  -hCG
levels failed to decline by at least 15% between days 4 and
7. A successful response to MTX was defined as the resolu-
tion of the  -hCG level less than 10 IU/mL. Treatment failure
was defined as the need to undergo surgical intervention for
women with signs of presumed tubal rupture (i.e., hemody-
namic instability, falling hematocrit level, or sonographic
visualization of free fluid outside the pelvis) or for women for
whom three injections of MTX failed to resolve the ectopic
pregnancy.
All continuous variables are expressed as the mean±SD
unless otherwise specified. T-test, chi-square test, and ANOVA
were performed using SPSS software (SPSS 10.0, Inc, Chicago,
IL, U.S.A.). p<0.05 was considered statistically significant.
RESULTS
During the study period, 126 patients were treated with
MTX. Among these patients, 85 patients (73 of which were
completely resolved and 12 of which underwent operation
due to ectopic rupture) who were once injected with MTX
were excluded. 2 patients who underwent operation on their
requests after the first injection of MTX were excluded as
well, making the remaining 39 patients the subjects of this
study. Among the 39 patients, 33 were injected with the 2nd
dose of MTX and 27 were cured. Of the 6 who were inject-
ed with the 3rd dose of MTX, all were cured. Therefore, the
success rate for the repeated injections was found to be 84.6%
(33/39) in our study (Fig. 1).
For the purpose of analysis, we classified the patients into
two groups; patients whose ectopic pregnancies resolved after
receiving repeated injections were classified as group 1 and
patients who underwent operation due to ectopic rupture
after repeated injections were classified as group 2. There
were no statistical differences with age, gestational age, gra-
vidity, history of ART, and symptoms such as lower abdom-
inal pain and/or vaginal spotting between group 1 (n=33)
and group 2 (n=6). Moreover, no statistical differences were
found in the size of ectopic mass on days 1 and 7, gestation-
al sac size, and the pregnancy site in sonographic findings
between two groups (Table 1). Also, although the  -hCG
levels of group 2 on days 1, 4, and 7 were all statistically high,
there were no statistical differences in changes of  -hCG
levels from days 1 to 4, from 4 to 7, and from 1 to 7 between
the two groups (Table 2). 
We then divided group 1 into groups 1-a and 1-b; group
1-a consisted of patients who showed a decrease in  -hCG
level from day 4 to 7 and group 1-b consisted of patients who
showed an increase in  -hCG level. When comparing the
three groups, group 1-a, 1-b, and 2, a significantly higher
-hCG level was observed in group 2. We also found that
the changes in  -hCG level from day 4 to 7 were significantly
different among the groups, with a larger increase rate observed
in group 1-b compared to group 2. On the other hand, the
three groups did not show any difference in the increase rate
of  -hCG level from day 1 to 4 and day 1 to 7. Also, inter-
Fig. 1. Outcome of ectopic pregnancy patients treated with MTX.
Ectopic Pregnancy 126 patients
Single dose: 87 patients repeated dose: 39 patients
73 resolved 12 ruptured 2 refused 2nd dose: 33
27 resolved
6 ruptured
6 resolved
3rd dose: 6
*unpaired t-test, 
� chi-square test, 
� one-sample t-test.
Group 1 
(n=33)
Group 2
(n=6)
p-value
Day 1 mass size (cm) 1.8±1.5 2.5±0.7 0.2844*
Day 7 mass size (cm) 2.0±1.5 1.9±1.2 0.8856*
p-value 0.0603
� 0.2632
�
Gestational sac size (cm) 0.6±0.7 0.7±0.6 0.6044*
Presence of yolk sac (%) 15.15 33.33 0.2857
�
Site (%)
Right 62.1 66.7
Left 37.9 33.3
p-value 0.1936
� 0.4142
�
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estingly, the resolution time between the two groups with
similar  -hCG levels, group 1-a and 1-b, did not show any
statistical difference (Table 3, Fig. 2).
Therefore, we suggest that the only significant success pre-
dictor of repeated injections is the initial  -hCG level. The
success rate is 96% (26/27) when initial  -hCG level is less
than 6,000 IU/mL and 58% (7/12), when greater than 6,000
IU/mL (OR=18.57, 95% CI 1.86-185.89).
DISCUSSION
Through many studies, initial  -hCG level, size of an ecto-
pic gestational mass, the presence of fetal cardiac activity, the
presence of free peritoneal fluid, and the presence of pelvic
pain or vaginal spotting have been accepted as predictors of
success for a single-dose regimen (6, 8-11). The initial  -
hCG level is known to be higher in patients who required a
second MTX injection, as compared to patients treated with
one dose, and Potter et al. (8). reported that the OR 3.8 indi-
cates the failure of repeated injections of MTX treatment.
However, predictors of success of repeated injections are not
well known. The small number of patients enrolled in most
studies and the exclusion of candidates for repeated injections
due to strict inclusion criteria, such as low  -hCG level or
small ectopic mass size, as in the study by Stovall et al. (7)
in which only 3.3% (4 of 120 patients) were injected with
the 2nd dose MTX, may account for this. In our studies, we
found that the initial  -hCG level was the only predictor of
success for the repeated injections, particularly in the cases
with initial  -hCG levels lower than 6,000 IU/mL.
It has to be noted that the early rise of  -hCG levels can
be observed in 50-70% of cases subjected to this medical
therapy, although it is not always associated with a clinically
relevant persistence of trophoblastic tissue (7, 12-15). Simi-
larly, in our study, the early rising of  -hCG level was observed
in 79.5% (31/39) of cases, our rates being higher since the
patients showing a decrease in  -hCG levels on day 4 were
mostly resolved after one dose injection and, as a result, exclud-
ed from this group. It still must be clarified why an initial
increase in  -hCG level can be observed before a complete
resolution and why it is present only in specific patients. Some
hypotheses have addressed the interpretation of this issue by
Natale et al. (14): 1) The long half-life (36 hr) of  -hCG level
must be considered for an initial lag time in serum  -hCG
clearance. 2) It is possible, but not yet unequivocally demon-
strated, that the initial response of the trophoblast to the
cytotoxic effect of methotrexate is the release of additional
-hCG into the circulation. 3) MTX is a folic acid analogue,
an antimetabolite that interferes with the synthesis of DNA
by inhibiting the action of dihydrofolate reductase; it inter-
rupts the synthesis of the purine nucleotide thymidilate and
the amino acids serine and methionine. This results in a cyto-
toxic effect on trophoblastic tissue. It is possible that, although
MTX is arresting mitosis in cytotrophoblasts, the syncytotro-
phoblastic mass still may be increasing and producing  -
hCG (16). 4) The metabolism of folinic acid in different pati-
ents might influence the effect of MTX. This is supported
by findings by Hajenius et al. (17), who observed that in
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Fig. 2. -hCG value profiles in groups 1-a, 1-b, 2.
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Group 2
Group 1-a
Group 1-b
Group 2
*t-test.
Group 1 
(n=33)
Group 2
(n=6)
p-value*
-hCG levels (IU/mL)
Day 1 3915.3±3281.3 8379.7±2604.6 0.0033
Day 4 4574.9±3627.5 9727.5±2838.9 0.0022
Day 7 4670.5±3689.8 9789.4±3023.5 0.0028
Changes of  -hCG levels (%)
Day 1→4 27.3±42.3 17.5±15.1 0.3189
Day 4→7 3.8±14.4 0.2±6.7 0.5545
Day 1→7 32.1±47.9 18.3±21.1 0.4961
Resolution time (day) 42.0±10.6 13.0±2.0
Table 2. Characteristics of  -hCG levels
*ANOVA.
Group 1-a
(n=16)
Group 1-b
(n=17)
Group 2
(n=6)
p-
value*
-hCG levels (IU/mL)
Day 1 3987.0±2980.7 3847.9±3632.4 8379.7±2604.6 0.0139
Day 4 4335.3±2285.0 4800.4±4616.3 9727.5±2838.9 0.0092
Day 7 4000.9±2022.9 5300.8±4745.7 9789.4±3023.5 0.0092
Changes of  -hCG levels (%)
Day 1→4 26.8±48.8 27.8±36.7 17.5±15.1 0.8592
Day 4→7 -6.5±4.1 13.5±13.9 0.2±6.7 <.0001
Day 1→7 17.9±44.2 45.5±48.6 18.3±21.1 0.1676
Resolution 42.1±11.7 41.9±9.8 13.0±2.0
time (day)
Table 3. Characteristics of  -hCG in groups 1-a, 1-b, 2Repeated MTX Injections in Ectopic Pregnancy 89
two groups of patients treated with multiple-dose MTX,
different protocols of folinic acid administration determined
different patterns of  -hCG curves. 
Additionally, it has been observed that the increase of  -
hCG level from day 4 to 7 is greater in group 1-b than in
group 2. This phenomenon can be partially explained by the
lower mitotic activity of the trophoblastic cells in cases with
smaller increases in  -hCG levels from day 4 to 7. Conse-
quently, in these cases, the trophoblastic tissue could result
in relative resistance to an antimitotic drug. Therefore, it would
be hasty to conclude the treatment as a failure based only on
the large increase rate in  -hCG level from day 4 to 7.
Natale et al. reported that at day 21 after the medical treat-
ment,  -hCG levels are similar for all patients undergoing
resolution; thus, when it occurs, the rapid rise of  -hCG
levels is associated with a rapid decrease after day 3 (14).
Accordingly, in this study, similar  -hCG levels in patients
undergoing resolution were observed at day 42. 
According to Gamzu et al., the initial size of the ectopic
mass was thought not to be related to the success of the MTX
treatment and that MTX treatment in tubal pregnancy was
followed by an initial increase in the size of the ectopic mass;
thus such enlargement of the ectopic mass should not be
considered as a higher risk for failure of treatment (18). In
our sonographic findings, there was no statistical difference
in the initial size of ectopic mass between groups 1 and 2.
Although the size of ectopic mass increased in group 1 and
decreased in group 2 from day 1 to 7, such findings were
not statistically significant. In addition, although the pres-
ence of yolk sac or the presence of fetal cardiac activity on
TVS was considered to be a significant predictor of treatment
failure (8), the presence of yolk sac was not statistically dif-
ferent between the two groups in our study. Regarding fetal
cardiac activity, only one patient was recognized; the pres-
ence of fetal cardiac activity is known to be highly relevant
to the high  -hCG level (10). It is most likely that such cases
were not included in our study, since most patients would
have failed on the 1st treatment of MTX before a second injec-
tion was taken into consideration. 
In conclusion, the initial  -hCG level is the only signifi-
cant predictor of success of repeated injections, particularly
when the  -hCG level is below 6,000 IU/mL. Also, predict-
ing treatment failure based strictly on a high increase of  -
hCG level from day 4 to 7 may be a hasty judgment.
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